Clinically studied for knee comfort, mobility & joint function
A 12-week, prospective, randomised, double-blind, placebo-controlled human clinical study in 100 adults with mild-to-moderate knee osteoarthritis evaluated joint comfort, stiffness, mobility, daily physical function and inflammatory biomarkers.
Turmimax® BIO Knee OA Study
- Design
- Prospective, randomised, double-blind, placebo-controlled
- Participants
- N = 100 adults, 40–75 yrs, mild-to-moderate knee OA (KL Grade 2)
- Intervention
- Turmimax® BIO 200 mg/day vs placebo
- Duration
- 84 days (assessments at screening, Day 42, Day 84)
- Primary endpoints
- Total WOMAC, WOMAC pain, stiffness, physical function, VAS
- Secondary endpoints
- ESR, hs-CRP, IL-6, Leukotriene B4, MMP-3
- Safety
- Vitals, CBC, LFT, RFT, lipids, glucose, urinalysis, AEs
Results by Day 84
Clinical Efficacy Progress
Measures knee-joint pain during movement, walking, and resting.
Statistical significance p < 0.01 observed across all main sub-scores by Day 84.
Inflammatory & cartilage biomarkers
| Biomarker | Turmimax® BIO | Placebo |
|---|---|---|
| IL-6 | 5.84 → 4.75 ng/L | 5.95 → 6.78 ng/L |
| Leukotriene B4 | 653.79 → 587.52 ng/L | → 725.93 ng/L |
| MMP-3 | 64.98 → 55.96 ng/mL | 69.12 → 72.64 ng/mL |
| hs-CRP | 5650 → 5154 ng/mL | 5740 → 6087 ng/mL |
| ESR (Day 84) | 11.78 mm/h | 13.79 mm/h (p = 0.0108) |
Well tolerated across 84 days
No serious adverse events were reported in the supporting product document; the clinical presentation described only minimal side effects. Safety assessments included monitoring of vital signs, complete blood count (CBC), liver and renal function, lipid profile, fasting blood glucose, and urinalysis.
Meaningful joint-health support
Turmimax® BIO at 200 mg/day supported clinically meaningful improvements in total WOMAC, pain, stiffness and the ability to perform daily activities, with favourable changes in IL-6, Leukotriene B4, MMP-3, hs-CRP and ESR.